- Home
- APXI vs ZOM Comparison
APXI vs ZOM Comparison
Compare APXI & ZOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APXI
- ZOM
- Stock Information
- Founded
- APXI 2021
- ZOM 2015
- Country
- APXI United States
- ZOM United States
- Employees
- APXI N/A
- ZOM N/A
- Industry
- APXI Blank Checks
- ZOM Biotechnology: Pharmaceutical Preparations
- Sector
- APXI Finance
- ZOM Health Care
- Exchange
- APXI Nasdaq
- ZOM Nasdaq
- Market Cap
- APXI 117.6M
- ZOM 135.9M
- IPO Year
- APXI 2021
- ZOM N/A
- Fundamental
- Price
- APXI $11.87
- ZOM $0.13
- Analyst Decision
- APXI
- ZOM
- Analyst Count
- APXI 0
- ZOM 0
- Target Price
- APXI N/A
- ZOM N/A
- AVG Volume (30 Days)
- APXI 5.8K
- ZOM 7.1M
- Earning Date
- APXI 01-01-0001
- ZOM 11-07-2024
- Dividend Yield
- APXI N/A
- ZOM N/A
- EPS Growth
- APXI 43.43
- ZOM N/A
- EPS
- APXI 0.24
- ZOM N/A
- Revenue
- APXI N/A
- ZOM $26,727,000.00
- Revenue This Year
- APXI N/A
- ZOM $36.75
- Revenue Next Year
- APXI N/A
- ZOM $14.92
- P/E Ratio
- APXI $49.25
- ZOM N/A
- Revenue Growth
- APXI N/A
- ZOM 11.33
- 52 Week Low
- APXI $11.06
- ZOM $0.12
- 52 Week High
- APXI $12.89
- ZOM $0.23
- Technical
- Relative Strength Index (RSI)
- APXI 65.08
- ZOM 52.93
- Support Level
- APXI $11.85
- ZOM $0.12
- Resistance Level
- APXI $11.86
- ZOM $0.16
- Average True Range (ATR)
- APXI 0.01
- ZOM 0.01
- MACD
- APXI -0.00
- ZOM 0.00
- Stochastic Oscillator
- APXI 100.00
- ZOM 36.58
About APXI APx Acquisition Corp. I
APx Acquisition Corp I is a newly incorporated blank check company.
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.